




To  the  Editor:  Varicella-zoster 
virus (VZV), a human herpesvirus, is 
the causative agent of varicella (chick-
enpox)  and  herpes  zoster  (shingles). 
Worldwide,  children  are  routinely 
vaccinated with a live attenuated vari-
cella vaccine containing the Oka vac-
cine (vOka) strain of VZV, originally 
developed  in  Japan  (1–3). Although 
the  risk  for  secondary  transmission 
of the vOka strain from immunocom-
promised  vaccinees  to  susceptible 
persons is relatively high, the risk for 
transmission from immunocompetent 
vaccinees is low (1). We report sec-
ondary transmission of the vOka strain 
from an immunocompetent girl with a 
history of varicella vaccination to her 
healthy susceptible brother.
Herpes  zoster  developed  in  a 
healthy  3-year-old  girl  2  years  after 
she had received the varicella vaccine 
(lot VZ040; Biken, Osaka, Japan). She 
received oral acyclovir treatment and 
fully recovered by day 19 after herpes 
zoster onset. On the same day that the 
girl recovered, her immunocompetent 
2-year-old brother was found to have 
fever and a rash consisting of 10–20 
papulovesicles; mild varicella was di-
agnosed. The boy had no known his-
tory of contact with persons infected 
with varicella or with persons who ad-
ministered the varicella vaccine. After 
receiving oral acyclovir treatment, the 
boy recovered without systemic com-
plications.
On day 19 after the girl’s onset of 
herpes zoster, an enzyme immunoas-
say (Denka Seiken, Tokyo, Japan) con-
firmed the presence of VZV-specific 
immunoglobulin  (Ig)  G  (titer  48.9, 
well above the detection limit of 2.0) 
but not IgM. The boy showed serocon-
version of VZV-specific IgG from a ti-
ter of <2.0 on day 3 after his disease 
onset to 19.3 on day 30. Although ve-
sicular fluid or crust specimens were 
obtained from both children, only the 
specimens from the boy contained de-
tectable amounts of VZV DNA.
To determine whether vOka or a 
wild-type VZV strain caused the va-
ricella in this boy, we performed PCR 
to amplify the entire region of gene 
62 and determine its sequence, as de-
scribed previously (4). The DNA se-
quence of the PCR product matched 
that  of  the  vOka  sequence  with  the 
exception of a single wild-type nucle-
otide substitution at position 105705 
(Figure,  GenBank  accession  no. 
AB497598).  Restriction  fragment 
length polymorphism (RFLP) analysis 
of the PCR products of the open read-
ing frame (ORF) 38 and ORF54 loci 
using PstI and BgII (5) demonstrated 
that  the  strain  had  a  vOka-like  pat-
tern, i.e., PstI-BgII+. Furthermore, the 
vOka-specific sequences at positions 
5,745 and 94,167 were conserved in 
the strain. Taken together, these results 
indicate that the strain in the boy likely 
was derived from the vaccine but was 
not a recombinant between the Biken 
vOka strain and a wild-type virus.
Commercial  varicella  vaccines 
produced  by  major  manufacturers 
such as Biken, Merck (Rahway, NJ, 
USA),  and  GlaxoSmithKline  Bio-
logicals (Rixensart, Belgium) possess 
similar  immunogenicity  and  safety 
characteristics (2,3,6). Adverse events 
involving  the  vOka  products  from 
Merck  (e.g.,  rash,  varicella,  herpes 
zoster, neurologic complications, and 
secondary  transmission)  have  been 
reported at an overall rate of 3.4–5.3 
events/10,000  doses  given  in  the 
United States (2,6). Six cases of sec-
ondary transmission from 5 immuno-
competent persons who had received 
vOka  made  by  Merck  have  been 
documented  (2,7,8).  Unfortunately, 
the association of vOka from Merck 
with some of those cases was defined 
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Figure. Sequence of gene 62 from patient with varicella from secondary transmission of 
Oka vaccine strain (vOka). The diagram at the top shows the structure of gene 62. Amino 
acid residues are numbered 1–1310 from the amino terminus to the carboxyl terminus. 
Vertical lines indicate the positions of 15-nt base differences between vOka (GenBank 
accession no. AB097932) and parental (pOka, accession no. AB097933) strains. The 15 
boldface and broken lines show substitutions with and without amino acid (aa) alterations, 
respectively. The charts show a comparison of the gene 62 sequences among vOka, 
pOka, Dumas (accession no. X04370), and the strain isolated from the secondary case-
patient (accession no. AB497598). The black, white, and gray boxes denote pOka-type 
substitutions, vOka-type substitutions, and mixed-type substitutions (mixture of pOka and 
vOka nucleotides), respectively. NCR, noncoding region.LETTERS
by RFLP analyses of only 1 or 2 loci 
(2,7). Although 5 of the 6 cases of sec-
ondary transmission were linked with 
vOka-associated cases of varicella, 1 
was transmitted from a vaccinee with 
herpes zoster (7). The fact that the sib-
ling reported in that case was already 
vaccinated before varicella developed 
confounds the case.
Postmarketing  surveillance  con-
ducted in Japan by Biken and the gov-
ernmental Relief Systems for Adverse 
Reactions have identified no cases of 
secondary transmission since Biken’s 
vOka was licensed in 1985 (Y.G. and 
N.I., unpub. data). Thus, the case re-
ported here is considered to be rare in 
that vOka was transmitted to a healthy 
susceptible  person  through  close 
contact  with  a  vaccinee  with  herpes 
zoster.
vOka is composed of a mixture 
of genotypically distinct virus strains 
that have 15 base substitutions in gene 
62  compared  with  the  parental  Oka 
strain. Gomi et al. have suggested that 
the amino acid alterations in the gene 
62  products  of  vOka  are  associated 
with the characteristics of vOka, i.e., 
slower growth and less efficient cell-
to-cell  spreading  in  vitro  compared 
with parental Oka (4). Previous stud-
ies have suggested that some alleles 
(positions  107797,  105169,  105356, 
and 108838) in gene 62 were impli-
cated in the formation of vaccine-as-
sociated rash (9,10). The virus in the 
case-patient  reported  here  contained 
1 synonymous nucleotide substitution 
from Biken’s vOka to a wild-type at 
position 105705 in gene 62. Because 
no such alteration was detected in the 
final Biken vOka products, informa-
tion about the in vivo process of natu-
ral selection for the particular genetic 
profile is needed.
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Aichi Virus Strains 
in Children with 
Gastroenteritis, 
China 
To  the  Editor:  Aichi  virus,  a 
member  of  the  Kobuvirus  genus  of 
the Picornaviridae family (1,2), is a 
positive-sense,  single-stranded  RNA 
virus with a genome of 8,280 nt and 
a poly(A) tail. The single, large open-
reading frame (ORF) encodes a poly-
protein of 2,432 aa that is cleaved into 
the typical picornavirus structural pro-
teins (VP0, VP3, VP1) and nonstruc-
tural proteins (2A, 2B, 2C, 3A, 3B, 
3C, 3D) (2,3). Based on the phyloge-
netic analysis of 519-bp sequences at 
the 3C–3D (3 CD) junction, Aichi vi-
ruses can be divided into 2 genotypes, 
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